Market Research on Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

To access full report with TOC, please visit Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 14, 38, 23, 85, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Abeona Therapeutics Inc Achillion Pharmaceuticals Inc Adamis Pharmaceuticals Corp Advanced Inhalation Therapies (AIT) Ltd Advinus Therapeutics Ltd AlgiPharma AS Allinky Biopharma Alteogen Inc Amakem NV Angiocrine Bioscience Inc Angion Biomedica Corp apceth Biopharma GmbH Apellis Pharmaceuticals Inc Aridis Pharmaceuticals LLC Astellas Pharma Inc AstraZeneca Plc Asubio Pharma Co Ltd Axikin Pharmaceuticals Inc Bayer AG Beech Tree Labs Inc Bioneer Corp Boehringer Ingelheim GmbH C4X Discovery Holdings PLC Carolus Therapeutics Inc Cellular Biomedicine Group Inc Celon Pharma SA Chiesi Farmaceutici SpA Circassia Pharmaceuticals Plc CSL Ltd Cytokinetics Inc Daiichi Sankyo Company Ltd Diffusion Pharmaceuticals Inc Domainex Ltd Enterprise Therapeutics Ltd Errant Gene Therapeutics LLC F. Hoffmann-La Roche Ltd Foresee Pharmaceuticals LLC Galapagos NV Gilead Sciences Inc GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Grifols SA Hanmi Pharmaceuticals Co Ltd iCeutica Inc InMed Pharmaceuticals Inc Innate Pharma SA Insmed Inc Intech Biopharm Ltd Invion Ltd Jiangsu Hansoh Pharmaceutical Group Co Ltd Johnson & Johnson KaloBios Pharmaceuticals Inc Kissei Pharmaceutical Co Ltd Kyowa Hakko Kirin Co Ltd Medestea Research & Production SpA MedImmune LLC Mereo Biopharma Group Plc Meridigen Biotech Co Ltd Microbion Corp Novartis AG Odan Laboratories Ltd OPKO Health Inc Orchid Pharma Ltd Orion Oyj Pfizer Inc Pharmaxis Ltd Promedior Inc ProMetic Life Sciences Inc Proteostasis Therapeutics Inc Pulmagen Therapeutics LLP Pulmatrix Inc Qu Biologics Inc Quark Pharmaceuticals Inc Re-Pharm Ltd Regeneron Pharmaceuticals Inc Respira Therapeutics Inc Respiratorius AB rEVO Biologics Inc Rhizen Pharmaceuticals SA SATT North SAS Seoul Pharma Co Ltd sterna biologicals Gmbh & Co KG Sun Pharma Advanced Research Company Ltd Sunovion Pharmaceuticals Inc Synedgen Inc Syntrix Biosystems Inc Takeda Pharmaceutical Company Ltd Teva Pharmaceutical Industries Ltd Therabron Therapeutics Inc Theravance Biopharma Inc Torrent Pharmaceuticals Ltd Unizyme Laboratories A/S Vectura Group Plc Verona Pharma Plc Vertex Pharmaceuticals Inc Yuhan Corp Yungjin Pharm Co Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###